A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas
Phase 2
Recruiting
- Conditions
- Dercum's Disease
- Interventions
- Drug: CBL-514 injection
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06303570
- Locations
- 🇺🇸
Investigational Site 01, O'Fallon, Missouri, United States
A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat.
Phase 2
Completed
- Conditions
- Subcutaneous Fat
- Interventions
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 173
- Registration Number
- NCT06005441
- Locations
- 🇺🇸
Investigational Site 1, Omaha, Nebraska, United States
A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2)
Phase 2
Completed
- Conditions
- Cellulite
- Interventions
- Drug: CBL-514 injection
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 23
- Registration Number
- NCT05836779
- Locations
- 🇺🇸
Investigational Site 4, Coral Gables, Florida, United States
🇺🇸Investigational Site 2, New York, New York, United States
🇺🇸Investigational Site 1, Encino, California, United States
A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat
Phase 2
Completed
- Conditions
- Subcutaneous Fat
- Interventions
- Drug: CBL-514 InjectionOther: 0.9% Sodium Chloride
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 107
- Registration Number
- NCT05736107
- Locations
- 🇺🇸
Investigational site 1, Pflugerville, Texas, United States
A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 1)
Phase 2
Completed
- Conditions
- Cellulite
- Interventions
- Drug: 40 mg CBL-514Drug: 60 mg CBL-514Drug: 80 mg CBL-514
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT05632926
- Locations
- 🇺🇸
Investigational Site 2, New York, New York, United States
🇺🇸Investigational Site 1, Encino, California, United States
A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With Dercum's Disease Lipomas
Phase 2
Completed
- Conditions
- Dercum's Disease
- Interventions
- Drug: 15 mg CBL-514 per injectionDrug: 10 mg CBL-514 per injection
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2023-04-20
- Lead Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT05387733
- Locations
- 🇺🇸
Karen L. Herbst, MD, PC, Tucson, Arizona, United States
A Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2022-07-15
- Lead Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT05234736
- Locations
- 🇺🇸
DermResearch Inc, Austin, Texas, United States
A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)
Phase 2
Completed
- Conditions
- Subcutaneous Fat
- Interventions
- Drug: CBL-514 InjectionOther: Placebo
- First Posted Date
- 2021-05-21
- Last Posted Date
- 2023-04-24
- Lead Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 75
- Registration Number
- NCT04897412
- Locations
- 🇦🇺
Investigational site 5, Melbourne, Victoria, Australia
🇺🇸Investigational site 1, Chicago, Illinois, United States
🇺🇸Investigational site 2, Omaha, Nebraska, United States
A Phase 1 Study to Evaluate the Safety and Tolerability of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy Volunteers
- First Posted Date
- 2021-01-07
- Last Posted Date
- 2021-01-07
- Lead Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT04699669
- Locations
- 🇦🇺
Investigational site, Melbourne, Australia
A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat
- First Posted Date
- 2021-01-07
- Last Posted Date
- 2021-01-08
- Lead Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 43
- Registration Number
- NCT04698642
- Locations
- 🇦🇺
Investigational site, Melbourne, Australia
© Copyright 2025. All Rights Reserved by MedPath